PDS Biotechnology shares are trading higher after the company announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in the March 10, 2026 issue of Journal of Clinical Oncology Oncology Advances.